Data demonstrate that SOT101 monotherapy and SOT101 in combination with pembrolizumab have a favorable safety profileEncouraging efficacy signals were observed for both SOT101 monotherapy and SOT101 in combination with pembrolizumab, even in patients with checkpoint-inhibitor relapsed and refractory tumors15 out of.
Investegate announcements from SOTIO Biotech, Data from SOTIO’s Phase 1/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors
Data demonstrate that SOT101 monotherapy and SOT101 in combination with pembrolizumab have a favorable safety profileEncouraging efficacy signals were observed for both SOT101 monotherapy and SOT101 in
Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual MeetingSOTIO will share interim safety and efficacy results from SOTIO’s AURELIO-03 study on Saturday, June 4AURELIO-03 is a Phase 1/1b dose escalation study of the interleukin-15 superagonist SOT101 as monotherapy an.